Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001704
Chunk: 11

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 11
---
 Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Both Internal and External Innovation Will B e Integral to Long Term Success © Copyright DYNAVAX 2025 S ource: Dynavax internal data and company estimates 1 In April 2022, the CDC’s ACIP expanded its recommendations for hepatitis B vaccination to include all adults aged 19 - 59 and adu lts aged 60+ with risk factors for hepatitis B. 2 Dynavax’s internal R&D candidates include, but are not limited to, novel shingles, plague, pandemic influenza, and Lyme disea se vaccine programs While HEPLISAV - B Has Been Highly Successful, Long - term Platform Diversification Will Be Key to Sustaining Growth Total Addressable Market : $615M In April 2022, the CDC’s ACIP announced new universal adult recommendation for hepatitis B vaccination 1 Internal R&D Shingles, Plague, Pandemic Flu, Lyme Disease 2 $36M 2030 2020 Corporate Development 2024 $ 268 M Expect double - digit CAGR for HEPLISAV - B net product sales through 2030 Total addressable hepatitis B market opportunity is expected to crest in 2030 13 | Total Addressable Market: $900M+ Substantial long - term opportunity in hepatitis B due to ongoing penetration of U.S. adult market and continued gains in market share Revenue:

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Identify Strategic Opportunities to Accelerate Growth • Continue disciplined allocation of capital aligned with corporate strategy to deliver long - term value through internal and external innovation • Explore external opportunities with high synergy assets in vaccines, or other modalities in infectious diseases, to further leverage our expertise and capabilities Our Strategy Drive Growth in HEPLISAV - B • Achieve at least 60% total U.S. market share by 2030 • Maximize total addressable market focused on top retailers and IDNs based on the ACIP Universal Recommendation • Leverage foundational commercial asset to support company growth and pipeline development​ Advance Differentiated Vaccine Pipeline • Deliver on our innovative and diversified pipeline leveraging CpG 1018® adjuvant with proven antigens​ • Build